Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss

30 Mar 2022

• By Ayisha Sharma

Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.

open road in desert — The Road To Success Is Clear For Tiragolumab Despite A Short-Term Setback • Source: Alamy

Roche Holding AG should bounce back after its lead anti-TIGIT asset tiragolumab failed a Phase III study in the difficult-to-treat indication small-cell lung cancer as experts hold out more hope for the asset in non-small cell lung cancer.

The Swiss major today revealed that tiragolumab combined with the firm’s standard of care PD-L1 inhibitor Tecentriq (atezolizumab) plus chemotherapy...